Vasopressin market

Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by Application, (Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock and Ventricular Tachycardia & Fibrillation), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Request Free Sample

Sep 2021
CMI4646
189 Pages
Excel & Pdf
Pharmaceutical

Summary

Vasopressin is antidiuretic hormone. It is naturally secreted by the pituitary gland, which acts on the kidneys and blood vessels. Vasopressin is used in the treatment of diabetes insipidus and certain conditions of the stomach after surgery or during abdominal x-rays. It is administered into a muscle or under the skin, or into a vein.

The global vasopressin market is estimated to be valued at US$ 1,112.6 million in 2021 and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).

Figure 1. Global Vasopressin Market Share (%) in Terms of Value, By Region, 2021

Increasing prevalence of autonomic dysreflexia (AD) is expected to drive growth of the global vasopressin market.

According to the National Center for Biotechnology Information (NCBI) 2017, the prevalence of AD in patients with spinal cord injury (SCI) has been reported to range from 20 to 70%, and it is known to occur in over 90% of patients with cervical or upper thoracic SCI.

Vasopressin Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 1,112.6 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	14.7%	2028 Value Projection:	US$ 2,912.0 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection By Application: Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock, Ventricular Tachycardia & Fibrillation By End User: Hospital, Clinics, Others
Companies covered:	Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals
Growth Drivers:	Increasing prevalence of autonomic dysreflexia (AD) Approval of Vasopressin Drug
Restraints & Challenges:	Potential side effects of Vasopressin Drugs

Figure 2. Global Vasopressin Market Share (%), by Type, 2021

The increasing regulatory approvals for vasopressin drug is expected to drive the market growth over the forecast period. For instance, in June 2021, Eagle Pharmaceuticals, Inc., announced that the U.S. Food and Drug and Administration priority review for the company’s abbreviated new drug application for its vasopressin.

The Eagle Pharmaceuticals, Inc., company’s response to the Complete Response Letter (CRL) was submitted on June 15, 2021. The U.S. FDA assigned a Generic Drug User Fee Amendments/Act GDUFA date of December 15, 2021

Global Vasopressin Market– Impact of Coronavirus (COVID-19) Pandemic-

The recent increasing cases of people suffering from Novel corona virus is expected to sudden increase of cardiac syndrome risk amongst people . This is leading the pharma sector to focus on research and development on advanced vasopressin drugs for treatment purposes. This is expected to boost the growth of the global market in the near future.

Global Vasopressin Market- Restraint

The major factor that is expected to hinder growth of the global vasopressin market include complication resulting from the use vasopressin such as asthma, epilepsy, heart disease, and heart failure.

Key Players

Major players operating in the global vasopressin market include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals.

Table of Content

*Browse 35 market data tables and 32 figures on "Global Vasopressin Market” - Global forecast to 2028

N/A

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2021-2028)?

The global vasopressin market is estimated to be valued at US$ 1,112.6 million in 2021 and is expected to exhibit a CAGR of 14.7% between 2021 and 2028.

What are the major factors driving the market growth?

Increasing prevalence of autonomic dysreflexia (AD) and approvals of vasopressin drug are expected to drive the market growth over the forecast period.

Which is the leading end user segment in the market?

Hospital segment is expected to hold major market share during the forecast period.

Which region holds the largest market share in the market?

North America is expected to hold largest market share in the market.

Which are the major players operating in the market?

Major players operating in the market include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals.